Enhancement of Antitumor Immunity by CTLA-4 Blockade

Abstract

One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.

Cite this paper

Related papers

1. Innate Immune Recognition2002
2. Obesity is associated with macrophage accumulation in adipose tissue2003
3. Control of Regulatory T Cell Development by the Transcription Factor Foxp32003
4. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.1986
5. Cancer immunotherapy using checkpoint blockade2018